Delays here aren't cheap. Tufts CSDD estimates roughly $40,000 in direct daily clinical-trial costs across Phase II and III, plus close to $800,000 per day in unrealized sales value once a therapy is delayed to market. Meanwhile, an AACI survey found a 167-day median activation time against a National Cancer Institute target of just 90 days.
The good news: acceleration doesn't require cutting corners. It requires better sequencing, standardized documentation, and the right partners.
Key Takeaways
- Start-up delays compound across the entire trial lifecycle, so early discipline pays off downstream
- Parallel workstreams, standardized contracts, and central IRBs are the three highest-leverage accelerators
- Speed and compliance reinforce each other when governance is built in from day one
- CRO partners with regional regulatory fluency compress start-up timelines without sacrificing data integrity
Understanding the Clinical Trial Start-Up Timeline
Study start-up (SSU) is the specific window between protocol/project approval and first patient enrolled. It's a defined subset of the broader trial lifecycle, not the full study duration.
Key Phases of Start-Up
The typical SSU sequence includes:
- Protocol finalization and regulatory planning: locking scientific design before operational work begins
- Site feasibility and selection: identifying capable, willing investigators and facilities
- Ethics committee/IRB submissions: securing approval to proceed
- Contract and budget negotiations: finalizing terms with each site
- Site initiation and activation: training staff, confirming systems, opening enrollment
Benchmarks vary widely depending on where you start the clock. Tufts CSDD found 6.5 months from pre-study visit to first patient in for Phase I trials, and 10.4 months for Phase II–IV.
A separate 2024 industry analysis put site identification to SSU completion at nearly 8 months on average. With no single industry-wide standard, sponsors need consistent internal benchmarks of their own.
Common Causes of Start-Up Delays
Most study start-up (SSU) delays trace back to a handful of recurring culprits:
- Incomplete or late documentation — missing forms, outdated investigator CVs, incomplete regulatory packets
- Extended contract negotiations — disputes over payment terms, indemnification clauses, or IP rights
- Slow ethics/regulatory reviews — committees requesting additional information mid-cycle
- Site capacity constraints — overcommitted staff or facilities
- Inefficient stakeholder communication — unclear ownership between sponsor, CRO, and site
Contract negotiation alone can swing wildly. One peer-reviewed analysis found US site contract execution averaging 7.9 months, ranging from 2.5 to 17.2 months depending on the institution.
Central vs. Local IRB: The Data
| Study | Central Review | Local Review |
|---|---|---|
| Neuman et al., 2018 | 30.1 days | 65.9 days |
| Krafcik et al., 2018 | 27 days | 66 days |
| ACRP cohort (2,225 sites) | 78 days | 165 days |
The direction is consistent across every study: central review beats local review on approval speed. But it doesn't eliminate site-specific submissions or local ancillary approvals — it just clears one bottleneck faster.
Proven Strategies to Accelerate Start-Up Without Compromising Quality
Sponsors that hit aggressive activation targets treat start-up as a managed system, not a chain of handoffs. These six practices compress timelines without sacrificing quality or compliance.
1. Run workstreams in parallel, not sequentially. A 2024 Mayo Clinic pilot had project managers coordinate financial, regulatory, and operational work simultaneously. Of 41 pilot trials tracked, 35 hit the under-30-week activation goal, with a 24-week median. That's not a universal guarantee, but it shows parallel processing works when governance is tight.
2. Standardize contracts and payment schedules. Pre-approved agreement templates cut negotiation time significantly. One CTSA study found standardized agreements averaged 39 days versus 73 days for custom-negotiated contracts, nearly cutting the timeline in half.
3. Use central IRBs where permitted. Central IRB review consistently outpaces local review by weeks, and in multi-site studies the gap often stretches to months. A single review pathway also reduces conflicting revisions across sites.
4. Build feasibility on data, not optimism. Engage sites early in protocol development using historical performance indicators such as prior enrollment rates, regulatory responsiveness, and staff capacity, rather than assumptions.
5. Centralize communication. Regular status meetings, defined roles across sponsor/CRO/site teams, and a single source of truth eliminate the "who owns this" confusion that stalls timelines.
6. Build in governance and escalation triggers. Define thresholds (for example, flagging any task idle for 14+ days) and track status using a simple RAG (red/amber/green) dashboard. Clear escalation paths catch bottlenecks before they become crises.
Measuring and Managing Start-Up Performance
You can't accelerate what you don't measure. Core metrics worth tracking:
- Cycle time to activation (site identification through activation-ready)
- Contract and budget turnaround (draft to fully executed agreement)
- Regulatory approval timelines (submission to IRB approval)
- Early enrollment rates (activation to first patient enrolled)
Report medians and upper-percentile figures, not just averages — a single average can hide a long tail of struggling sites. Continuous review against these benchmarks shows which stage is the real bottleneck.
Risk-based prioritization turns those insights into action. Activating high-recruiting regions first, based on historical performance, gets enrollment moving faster even while slower sites catch up.
How a Global CRO Partner Supports Faster, Compliant Start-Up
This is where an experienced, multi-regional partner speeds start-up without cutting corners. DRK Research Solutions operates across Europe, the Middle East, Asia, Africa, and the Americas, with regional leadership in the UK, Southeast Asia, and the USA.
That local presence matters. IRB requirements, contracting norms, and ethics committee cadences differ by region. A template that works in Cambridge will not automatically clear review in Lahore or Nairobi.
DRK's end-to-end CRO model covers the start-up workstreams that usually stall in sequence:
- Site feasibility
- Regulatory documentation
- Contract support
- eCRF and data-system setup
The model is built so feasibility, contracting, and regulatory submission move concurrently rather than in a strict queue. GxP-aligned processes (ICH-GCP, EU GMP, US FDA, MHRA, WHO PQ, PIC/S) keep those parallel workstreams from becoming shortcuts.
DRK also focuses on multi-regional trials and underserved low- and middle-income country markets. Since 2018, it has built MRCT capabilities and regulatory collaborations so sponsors can reach populations traditional trial geographies often miss, expanding patient access while keeping compliance consistent across every region involved.
Frequently Asked Questions
What is the average timeline for a clinical trial?
There's no single agreed-upon figure. Tufts CSDD benchmarks range from 6.5 to 10.4 months from pre-study visit to first patient enrolled, depending on trial phase. Total trial duration varies more widely by therapeutic area and complexity.
How long from Phase 3 to market?
Phase 3 trials typically run 1 to 4 years. After completion, the FDA targets 10 months for standard review and 6 months for priority review before a decision on approval.
What are the 5 stages of clinical trials?
Early Phase 1 (formerly Phase 0), Phase 1 (safety), Phase 2 (preliminary efficacy), Phase 3 (confirmatory safety and efficacy), and Phase 4 (post-approval monitoring).
What causes the most delays in study start-up?
Contract negotiations, IRB and ethics review timelines, and incomplete documentation are the three most-cited contributors across published research. Site capacity and communication gaps compound all three.
Can central IRBs really speed up trial start-up?
Yes. Multiple studies show central review cutting approval time roughly in half compared to local review (for example, 27 days versus 66 days in one analysis). It doesn't eliminate all site-specific work, though.
How can sponsors accelerate start-up without risking data quality or compliance?
Run feasibility, contracting, and regulatory work in parallel, standardize agreements and documentation, and partner with a CRO experienced in the specific regulatory regions involved. Governance and escalation pathways keep speed from becoming a compliance risk.
